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ABSTRACT: 
Background: Circulating serum levels of oxidized low-density lipoprotein, β2-glycoprotein I 
complex (oxLDL-GP), have been previously correlated with adverse cardiovascular events and 
have been shown to be reduced by consumption of enzymatically liberated extra virgin salmon 
oil (EVSO).  This mouse study measured the changes in the oxLDL-GP lowering effect when 
consuming EVSO with varying levels of EPA+DHA (eicosapentenoic acid and docosahexenoic 
acid)  as well as when consuming EVSO that was subjected to various processing treatments 
commonly carried out during fish oil production.  
 
Methods: Sprague Dawley mice were fed a diet containing eight different EVSO’s incorporated 
into a normal diet at the Human Equivalent Dose (HED) of 1000 mg for 8 weeks. Serum was 
collected at the start and at the end of the trial and the oxLDL-GP concentrations were measured 
using an ELISA assay. Statistical analysis of the results was carried out using a 1-tail, paired 
Student t-Test. 
 
Results: In order to lower circulatory oxLDL-GP levels, the mice had to consume a minimum of 
80 mg per day HED of EPA+DHA. Heat treatment of the EVSO did not affect this bioactivity 
but  hydrolysis  with  acid  or  base  and  re-esterification  to  the  triglyceride  form  or  significant 
oxidation (rancidity) rendered the oil inactive on this important cardio-vascular disease (CVD) 
biomarker.  
 
Conclusions: This result shows that harsh processing conditions on fish oils can lead to the 
destruction  of  biological  efficacy  in  spite  of  increasing  the  concentration  of  typical  fish  oil 
bioactive  constituents  such  as  EPA+DHA.  It  also  lends  support  to  the  developing  nutrition 
theory that eating highly-refined, processed or concentrated-ingredient supplements derived from 
functional foods may not be able to reproduce their full nutritive and health-benefiting effects. Functional Foods in Health and Disease 2014; 4(10):463-473                                                          Page 464 of 473 
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BACKGROUND: 
Atherosclerosis  is  a  multi-factor  chronic  pathologic  process  associated  with  significant 
cardiovascular morbidity and mortality. Over the past few years many trials have reported on the 
beneficial  effects  of  eating  fish  in  patients  with  preexisting  CVD  as  well  as  in  healthy 
individuals. [1]  Zhang et al, [2]
 showed that fish consumption was associated with a reduced risk 
from all-cause, ischemic heart disease and stroke mortality across 36 countries. In the Chicago 
Western Electric Study, [3] men who consumed 35g of fish daily had a 50% lower risk of death 
from coronary heart disease (CHD), as compared to the control group. Other epidemiological 
studies  have  also  reported  that  men  who  ate  at  least  some  fish  weekly  had  a  lower  (CHD) 
mortality rate compared to men who ate no fish in their diet. [4,5] The recent Nurses’ Health 
Study [6] has shown an inverse association between fish intake and CHD death on a dose-
dependent  curve.  In  another  population-based,  case-controlled  study,  a  50%  reduced  risk  of 
primary  cardiac  arrest  was  reported  between  fish  intake  and  risk  for  sudden  death  with 
consuming only two oily fish meals per week. [7]   
Some  studies,  such  as  the  Health  Professionals’  Follow-up  Study,  [ 8 ]  and  the  US 
Physicians’ Health Study [9] have not shown a beneficial effect from fish intake (and omega-3 
fatty  acids)  and  risk  of  any  CHD  nor  a  reduced  risk  of  total  myocardial  infarction  (MI)  or 
cardiovascular  mortality,  although,  as  appropriate  to  the  conclusions  of  this  paper,  fish 
consumption alone was related with a reduced risk of total mortality. More significantly, this 
seeming lack of an association between fish intake (and omega-3 fatty acids) and CHD incidence 
and mortality was also seen in the EURAMIC (European Multicenter Case-Control Study on 
Antioxidants,  Myocardial  Infarction  and  Breast  Cancer)  Study  [10] where  no  evidence  of 
reduced risk of MI was seen in spite of increased levels of adipose tissue DHA.  In fact, in 
extension to these studies that do not show a beneficial  effect, the Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study found that estimated omega-3 fatty acid intake from fish was 
actually associated with a trend towards increased risk of coronary death when adjusted for fatty 
acid types.[11]  
It is possible to arrive at some explanations for the conflicting data from the epidemiological 
studies due to the differences in definitions of sudden death, variable healthy lifestyle definitions, 
experimental design and test substances, different study populations and variability in the end 
points studied. [12] One explanation, based on an analysis of 11 studies, is that the protective 
effect of fish consumption relates to the CHD risk status of the population studied [13]
 and that 
fish consumption reduces CHD mortality in high-risk but not low-risk populations. The type of 
fish  and  associated  lipid  biofactors,  besides  omega-3’s,  may  also  play  a  role  in  observing 
changes  is  CVD.    Oomen  et  al  [14] reported  a  lower  CHD  mortality  in  populations  that 
consumed fatty fish but not lean fish while other epidemiological studies have hypothesized on 
the adverse effects of methylmercury, an environmental contaminant found in certain fish that 
may diminish the health benefits of omega-3 fatty acids. [15] Another important fatty acid, α-
linolenic acid, has recently shown significant effect on lowering the risk of MI and fatal ischemic 
heart disease. [16]  Functional Foods in Health and Disease 2014; 4(10):463-473                                                          Page 465 of 473 
 
Several epidemiological studies have also examined the relationship between fish intake and 
stroke incidence. Zutphen showed a lowering of the unadjusted hazard risk ratio for men who 
consumed an average of 20g/day of fish. [17] Yet again, in other studies like the Lyon Diet Heart 
Study [18] (testing a Mediterranean-style diet enriched with α-linolenic acid) and the GISSI-
Prevention Study [19] (testing the effects of 850 mg of supplemental omega-3 fatty acids), there 
was no significant effect on the incidence of stroke. 
To assist in narrowing down the relationship between CVD and fish/fish oil intake many 
researchers have begun to study the dietary effect of fish/fish oil intake on specific serologic 
markers  of  inflammation  that  have  been  associated  with  cardiovascular  disease  (CVD) 
progression [20].  Friedman et al have shown that oral fish oil supplementation lowers C-reactive 
protein in serum as a potential indication of reduced inflammatory risk. [21] Recent clinical 
evaluations have shown that oxidized low-density lipoprotein is highly inflammatory with pro-
atherogenic properties that promote endothelial dysfunction.[22] Damsgaard et al have shown 
that  fish  oil  supplementation  lowers  plasma  triglyceride  levels  but  does  not  impact  other 
serological CVD biomarkers like oxLDL. [23] Unlike native LDL, oxLDL binds in vitro to β2-
glycoprotein I, a phospholipid-binding plasma protein, in a time- and temperature- dependent 
manner to form covalently bound stable oxidized low-density lipoprotein- β2-2-glycoprotein-1 
(oxLDL-GP) complexes. [24] The association of oxLDL-GP complexes with CVD severity and 
adverse outcomes in patients with associated inflammatory diseases has also been reported. [25]   
We have previously shown that a daily dietary supplement of 1000mg/day of EVSO reduces 
circulatory  levels  of  oxLDL-GP  in  healthy  human  subjects.  This  oxLDL-GP  concentration 
lowering effect was not observed with standard 18/12 fish oil or the control vegetable oil and 
minimally observed with other highly processed oils such as krill and algae. [26] 
The aim of this study is to examine the effect of varying the daily intake levels of the 
polyunsaturated  fatty  acids,  eicosapentenoic  acid  (EPA),  docosahexenoic  acid  (DHA),1  and 
various manufacturing unit-process steps such as treatment with acid, base, heat, and oxidation 
on  natural EVSO using  an ELISA  assay to  measure circulating serum  concentrations of  the 
oxLDL-GP CVD biomarker in Sprague-Dawley mice. Our results may lend some clarity to the 
highly varied epidemiological results of dietary fish and fish oil intake on CVD, by studying the 
impact of specific fish oil manufacturing processing steps on the CVD marker, oxLDL-GP. 
 
METHODS & MATERIALS: 
This study was conducted according to GCP guidelines issued by the ICH and CDSCO ethical 
guidelines in accordance with the laws and regulations of India where the trial was performed. 
The final approved protocol, informed consent documents, and all the study related documents 
were reviewed and approved by an Institutional Animal Ethics Committee before the start of the 
study.  
Study Design: 64 healthy Swiss Albino mice (Mus Musculus) of equal gender (females were 
nulliparous and non-pregnant) and up to 10 weeks in age completed this 8 week randomized 
open label study. Animals were acclimatized to the test conditions for a minimum period of 5 
days prior to the test. Prior to initiation of test item/placebo administration, the animals were 
randomly  allocated  to  the  eight  different  test  groups  (G1-G8)  using  the  `Group  Allocation` 
function in the MS Excel Add-in “Daniel´s XL Toolbar,” (http://xltoolbox.sourceforge.net/) in Functional Foods in Health and Disease 2014; 4(10):463-473                                                          Page 466 of 473 
 
such a way that weight variation of animals was within 20% of group mean. The animals were 
marked  individually  by  temporary  tail  marking  with  indelible  ink  and  cage  cards  during 
acclimatization and by micro tattooing of toe pads, after randomization.  
Following allocation to the study, each animal was assigned an individual cage card, labeled 
with species, strain, sex, project number, animal number, group number, dose level, and 
experiment start and end dates. 
Corn cob from M/s. Sparconn Lifescience, was used as bedding material. The average room 
temperature and relative humidity of experimental room were maintained between 19 to 23°C 
and 43 to 55%, respectively, during the entire study period.  Artificial light was set to give a 
cycle of 12 hours light and 12 hours dark. A minimum of 12 air changes per hour were provided 
to the animal room. The animals were offered a conventional laboratory rodent diet ad libitum 
supplied by M/s.  Nutrivet Life Sciences and water was provided ad libitum. 
Test  Formulations:  Seven  samples  of  EVSO  were  prepared  with  varying  levels  of 
EPA+DHA and different production treatments, as shown in Table 1 below.   
 
          Table 1. EPA/DHA composition and process treatment of test oils per group 
 
Group/Dose:   
G1  Sunflower oil / 206mg/kg/day (negative control) 
G2  EVSO 80mg/g EPA+DHA / 206mg/kg/day 
G3  EVSO 40mg/g EPA+DHA /103mg/kg/day+103mg/kg/day of 
sunflower oil 
G4  EVSO 120mg/g EPA+DHA / 206mg/kg/day 
G5  EVSO 180mg/g EPA+DHA / 206mg/kg/day 
G6  EVSO 120mg/g EPA+DHA after heat treatment / 
206mg/kg/day 
G7  EVSO 120mg/g EPA+DHA after hydrolysis & re-TG/ 
206mg/kg/day 
G8  EVSO 120mg/g EPA+DHA after air oxidation / 206mg/kg/day 
 
The mouse dose was selected based on the proposed human (60 kg weight) dose of the 
EVSO at 1000 mg/day. Based on body surface area calculations, the mouse equivalent dose was 
determined to be 206 mg/kg/day and hence this was applied across all groups.  
Mice in the Group G1 were fed a diet containing sunflower oil as the negative control. Mice 
in Group G2 were fed  the natural EVSO containing 80 mg/g of EPA+DHA as the positive Functional Foods in Health and Disease 2014; 4(10):463-473                                                          Page 467 of 473 
 
control group. In Group G3, the amount of EVSO was reduced by half to 103 mg/kg/day and the 
remainder of the fatty acid quantity was made up with 103 mg/kg/day of sunflower oil so that the 
mice only received 40 mg/kg/day of EPA+DHA. To increase the daily dose of EPA+DHA to 
120 mg/kg/day in Group G4 and to 180 mg/kg/day in Group G5, we used a selective lipase 
treatment  [
27]  to  increase  the  relative  EPA+DHA  in  the  EVSO  to  120  mg/g  and  180  mg/g 
respectively without impacting the overall quality of the oil.  Mice in Group G6 were given the 
same  EVSO  as  in  G4  containing  120mg/g  EPA+DHA  but  treated  with  heat  at  190C  for  5 
minutes to simulate vacuum molecular distillation.[
28]  Mice in Group G7 were given EVSO as 
in G4 but the EVSO was hydrolyzed with base and re-esterified with glycerol/acid as done in the 
standard fractional distillation step [
29] often carried out for producing EPA/DHA concentrated 
fish oils. Finally, the mice in Group G8 were given EVSO as in G4 but the EVSO had been 
oxidized (by air bubbling) to reach  a totox of 24 which is at the upper limit of the GOED 
standard. [30] 
Description of the ELISA Assay for oxLDL/β2GPI concentrations: To a pre-prepped 96 
micro well plate (Cayman Chemicals Inc., USA) 100 μL of mouse serum samples diluted 1:100 
in sample  diluent was added (100 mmol/L tris(hydroxymethyl)  aminomethane hydrochloride 
saline containing 2% BSA and 5 mmol/L magnesium chloride, pH 8.5) and allowed to incubate 
at  room  temperature  for  1  hour.  The  micro  wells  were  washed  four  times  with  phosphate-
buffered saline containing 0.05% polysorbate-20 between each step. Biotinylated 2E10 anti-body 
(IgG murine monoclonal anti-mouse ApoB-100) diluted in 20 mmol/L HEPES-saline containing 
2%  BSA  at  pH  7.4  was  added  to  the  micro  wells  and  incubated  for  30  minutes  at  room 
temperature,  followed  by  horseradish  peroxidase-streptavidin  for  30  minutes.  Color  was 
developed with tetramethylbenzidine/hydrogen peroxide for 30 minutes and the reaction stopped 
with 0.3N sulfuric acid. Optical density was read at a wavelength of 450 nm. The functional 
sensitivity was 0.05 U/ml. Serum oxLDL/β2GPI complex concentration (expressed in U/mL) 
was calculated against a reference curve generated from 3-fold serial dilutions of the reference 
serum. The specific interaction between oxidized LDL and β2GPI and the specificity of the assay 
for oxLDL/β2GPI complexes has been previously reported.[31] 
 
RESULTS: 
No incidences of mortality were noted in any group during the 8 weeks of study period. No 
treatment related clinical signs or symptoms were observed in any of the animals, throughout the 
study period.  
No significant difference was observed in the percentage body weight changes of treated 
animals as compared with the controls, throughout the treatment period.  
Food consumption in animals of the treatment groups was comparable to the control group.  
At gross necropsy, none of the animals of treatment groups showed any external or internal 
abnormal changes.   
        The eight treatment groups showed significantly different results based on both the total 
amount of daily EPA/DHA consumed as well as the different processing treatments carried out 
on the EVSO as shown in Table 3. Statistical analysis of each Group’s results was carried out 
using the paired, one-tailed student t-test.  
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 Table 2. EVSO Specifications per Group 
 
COMPONENTS  G1  G2  G3  G4  G5  G6  G7  G8 
Saturated Fatty acids  300  155  155  145  130  155  155  155 
Monounsaturated fatty acids  580  550  550  520  470  550  550  550 
Omega-3 fatty acids  20  160  160  200  255  155  160  160 
Omega-6 fatty acids  80  120  120  120  130  120  120  120 
Eicosapentaenoic acid  15  35  35  50  70  30  35  35 
Docosapentaenoic acid  < 5  15  15  15  15  15  15  15 
Docosahexaenoic acid  10  45  45  70  110  45  40  45 
Asthaxanthin (mcg/gm)  < 1  9  9  9  9  7  6  5 
TOTOX  8  12  12  12  12  11  15  27 
 
   *All fatty acids assayed as methyl esters in GC +/- 5mg/g 
 
 
   Table 3. Differential EVSO Feeding impact on serum oxLDL-β2-glycoprotein-I 
 
Group  Mean Start 
conc 
(U/mol) 
SD  Mean End 
conc (U/mol) 
SD  Percent 
Reduction in 
oxLDL-GP 
P value  t value 
G1  4.964  0.3368  4.897  0.2959  -1.35% 
a  0.3008  0.4944 
G2  4.975  0.2605  4.712  0.2642  -5.29% 
b  0.0326  2.0009 
G3  5.037  0.4207  4.925  0.4234  -2.22% 
a  0.3011  0.5331 
G4  5.135  0.2274  4.851  0.3207  -5.53% 
b  0.0381  1.9144 
G5  5.062  0.2615  4.775  0.2659  -5.67% 
b  0.0234  2.1802 
G6  5.012  0.2357  4.787  0.2696  -4.49% 
b  0.0488  1.7751 
G7  5.125  0.2314  5.062  0.2825  -1.23% 
a  0.3181  0.4836 
G8  5.087  0.3137  4.925  0.3693  -3.18% 
a  0.1796  0.9476 
 
   a = not statistically significant; b = statistically significant (P<0.05) 
 
 Functional Foods in Health and Disease 2014; 4(10):463-473                                                          Page 469 of 473 
 
DISCUSSION: 
Chronic inflammatory diseases  including atherosclerosis are  a major cause of morbidity  and 
mortality worldwide. Many studies as discussed above have shown the value of including oily 
fish in the diet for improved cardiovascular and cerebrovascular health[32] while other studies 
on fish oil supplements have shown mixed results. [33] A recent meta analysis of published 
studies[34] has even reported no correlation between omega-3 supplements and cardio-vascular 
health. Accumulating evidence suggests that certain oxidized low-density lipoprotein complexes, 
such as the serum circulating oxLDL-β2-glycoprotein-I assayed here, represent endogenously 
formed factors that may be useful for diagnosing vascular inflammation, plaque build-up and 
CVD progression. In this study, we used this important CVD biomarker to further define the role 
of different components in extra virgin salmon oil in CVD treatment. By selectively increasing 
and decreasing the concentration of EPA+DHA without impacting the other oil components in 
any way, we were able to examine the specific effect these omega-3’s had on modulating  serum 
circulating oxLDL-β2-glycoprotein-I. 
Group G2 in Table 2 shows that a minimum intake of a human equivalent dose (HED) of 80 
mg/day of EPA+DHA is required for significant (95% confidence; P < 0.05) lowering of serum 
concentrations of oxLDL-GP. At the same time, it is also apparent from the results of Groups G5 
and G6 that further increases in EPA+DHA HED to 120 mg/day and 180 mg/day did not lead to 
additional statistically significant decreases in serum levels of oxLDL-GP.  
Different processing treatment carried out on the EVSO also led to variable results.  Heat 
treatment of the EVSO (Group G6) did not affect the ability of the oil to lower serum levels of 
oxLDL-GP.  However,  both  acid/base  hydrolysis  followed  by  re-esterification  to  triglyceride 
esters (Group G7) and oxidative rancidity (Group G8), even to GOED acceptable fish oil capsule 
levels, eliminated the ability of the EVSO to reduce serum levels of oxLDL-GP, potentially 
making  these  processing  treatments  particularly  detrimental  to  the  ability  of  marine  oils  to 
benefit cardiovascular disease, as measured on the oxLDL-GP CVD biomarker.  
One  aspect  of  our  results  examines  the  effect  of  varying  levels  of  EPA+DHA  in 
nutraceutical marine oil intake ranging from HED of 40 mg/day to 180 mg/day to reduce serum 
concentration levels of the new cardio-vascular biomarker, oxLDL-GP. The results showed that a 
minimum intake of 80 mg/day of EPA+DHA was necessary to show a  statistically significant 
lowering of oxLDL-GP levels in serum but that increased intake did not significantly impact 
lowering of this critical CVD marker.  This result is consistent with other results for minimum 
required omega-3 intakes for CVD effect such as reported by Albert et al [35] at 5g per month of 
omega-3 intake.  
Another aspect of our results examined the effect of the various processing treatments on the 
ability of EVSO at reducing serum levels of oxLDL-GP at the same dose of EPA+DHA. We 
used the 120 mg/day dose of EPA+DHA as the standard, and when subjected to 180C heat, the 
bioactivity of the EVSO was preserved but reduced (Group G6). However, upon treatment with 
acid or base and re-esterification to the triglyceride form (Group G7), the EVSO completely lost 
its bioactivity and the ability to reduce serum levels of oxLDL-GP. Similarly, upon oxidation 
with air to the limit of acceptable totox levels in commercial fish oil products (Group G8), the 
EVSO  lost  its  ability  to  statistically  significantly  decrease  serum  levels  of  oxLDL-GP. 
Processing  of  foods  and  food  ingredients  often  exerts  a  major  effect  on  their  constituents, Functional Foods in Health and Disease 2014; 4(10):463-473                                                          Page 470 of 473 
 
especially the bioactive compounds. Liyana-Pathirana  et al [36], reported that using different 
milling platforms changed the phenolic content of two wheat cultivars and this was reflected in 
free  radical  and  reactive  oxygen  species  (ROS)  scavenging  capacity  and  iron  (II)  chelation 
capacity of the products.  Similarly processing of soybeans in the production of tofu greatly 
decreases the concentration of bioactive isoflavone compounds. [37] Our results are consistent 
with these reported losses of biological values in other overly processed foods.   
 
CONCLUSION: 
It may be concluded from our results that a minimum quantity of 80mg/day HED of EPA+DHA 
omega-3 acids is required to reduce the serum levels of oxLDL-GP and thus achieve a beneficial 
cardiovascular  effect,  but  that  increasing  the  amount  of  this  daily  intake  is  not  a  sufficient 
mechanism to further reduce circulatory oxLDL-GP serum levels. Instead, the presence of the 
maximum  natural  level  of  other  lipid  soluble  bio-factors  in  minimally  treated  salmon  oils 
(EVSO) seems to play a more important role in potentiating the effect of lowering oxLDL-GP 
serum  concentrations,  especially  as  observed  for  EVSO  that  has  been  subjected  to  harsh 
processing chemicals and solvents that reduce the presence of these bio-factors in the oil. 
Our  result  on  EVSO  reinforce  similar  studies  [38]  on  the  same  biomarker  that  show 
consuming  a  highly  processed  extract  of  a  functional  food  does  not  result  in  the  same 
quantitative biological effect as consuming the natural whole food or its minimally processed 
whole-food extract. 
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